Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00087776
Status:
COMPLETED
Last Update Posted:
2018-01-24
First Post:
2004-07-13
Brief Title:
Study of Taxoprexin Injection vs Dacarbazine in Patients With Metastatic Malignant Melanoma
Sponsor:
American Regent Inc
Organization:
American Regent Inc
Study Overview
Official Title:
Phase III Study of Taxoprexin Injection vs Dacarbazine in Patients With Metastatic Malignant Melanoma
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine In addition the response rate to each drug response duration time to progression and time to treatment failure will be measured Toxicity will be evaluated and compared between the two groups
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None